Melanoma is one of the most common causes of brain metastases (BM).
Despite recent therapeutic advances, survival in patients with brain metastases from melanoma (MBM) is dismal.
In this study, we analyse the effect of concomitant treatment with stereotactic radiotherapy (SRT) and immunotherapy on survival, and of the location of BM on survival.
